NEW YORK, October 5, 2017 /PRNewswire/ --
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration Company, announced today the launch of http://www.PainFreeCancer.com. This website is designed to provide a resource
for patients, doctors and caregivers dealing with the severe pain associated with late stage cancer metastases to the bone.
U.S. Food and Drug Administration approved Generic Strontium Chloride Sr89 Injection, USP; (Strontium-89) is a Non-Opioid
pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. In the body, Strontium-89 acts
similar to calcium and is preferentially taken up in osteoblastic tissue selectively localizing in bone mineral. Uptake of
strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic
involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Up
to 80% of patients report pain relief lasting for months.
Strontium Chloride Sr89 Injection, USP can be used in combination with other therapeutic drugs. Clinical studies have
demonstrated that the combination of alternating weekly chemohormonal therapies with Strontium-89 demonstrated a prolonged
progression-free and overall survival in patients.
Visit http://www.PainFreeCancer.com today.
Strontium Chloride Sr89 Injection, USP Usage and Indications:
Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the
blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active
osteogenesis, thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater
concentrations of strontium than surrounding normal bone. Strontium-89 is retained in metastatic bone lesions much longer than in
normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose
is retained in the bones. Strontium-89 is a pure beta emitter and Strontium-89 selectively irradiates sites of primary and
metastatic bone involvement with minimal irradiation of soft tissues distant from the bone lesions. (The maximum range in tissue
is 8 mm; maximum energy is 1.463 MeV.) Clinical trials have examined relief of pain in cancer patients who have received therapy
for bone metastases (external radiation to indexed sites) but in whom persistent pain recurred.
INDICATIONS AND USAGE: Strontium-89 Chloride Injection is indicated for the relief of bone pain in patients with painful
skeletal metastases. The presence of bone metastases should be confirmed prior to therapy.
CONTRAINDICATIONS: None known.
WARNINGS: Use of Strontium-89 (Sr89) in patients with evidence of seriously compromised bone marrow from previous therapy or
disease infiltration is not recommended unless the potential benefit of the treatment outweighs its risks. Bone marrow toxicity
is to be expected following the administration of Strontium-89, particularly white blood cells and platelets. The extent of
toxicity is variable. It is recommended that the patient's peripheral blood cell counts be monitored at least once every other
week. Typically, platelets will be depressed by about 30% compared to pre-administration levels. The nadir of platelet depression
in most patients is found between 12 and 16 weeks following administration of Sr89. White blood cells are usually depressed to a
varying extent compared to pre-administration levels. Thereafter, recovery occurs slowly, typically reaching pre-administration
levels six months after treatment unless the patient's disease or additional therapy intervenes. In considering repeat
administration of Sr89, the patient's hematologic response to the initial dose, current platelet level and other evidence of
marrow depletion should be carefully evaluated. Verification of dose and patient identification is necessary prior to
administration because Sr89 delivers a relatively high dose of radioactivity. Sr89 may cause fetal harm when administered to a
pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if
the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.
Women of childbearing potential should be advised to avoid becoming pregnant.
About Q BioMed Inc.
Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued
biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental
support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients
in need.
To stay up-to-date with Q BioMed developments, please visit http://www.qbiomed.com and sign up for our news distribution.
For more information, please visit http://www.PainFreeCancer.com
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock price. Factors that could cause actual results to differ
materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research
and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and
relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability
to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described
in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any
forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435
SOURCE Q BioMed Inc.